![Distribution of Lp(a) particle concentration values in the Framingham... | Download Scientific Diagram Distribution of Lp(a) particle concentration values in the Framingham... | Download Scientific Diagram](https://www.researchgate.net/publication/353102542/figure/fig2/AS:1043894041067520@1625895142216/Distribution-of-Lpa-particle-concentration-values-in-the-Framingham-cohort-and-AIM-HIGH.png)
Distribution of Lp(a) particle concentration values in the Framingham... | Download Scientific Diagram
![COMBINED LDL-C AND LIPOPROTEIN (A) LEVELS IN PREDICTION OF RESIDUAL ATHEROSCLEROTIC CARDIOVASCULAR DISEASE RISK: THE AIM-HIGH TRIAL (ATHEROTHROMBOSIS INTERVENTION IN METABOLIC SYNDROME WITH LOW HDL/HIGH TRIGLYCERIDES: IMPACT ON GLOBAL HEALTH OUTCOMES) COMBINED LDL-C AND LIPOPROTEIN (A) LEVELS IN PREDICTION OF RESIDUAL ATHEROSCLEROTIC CARDIOVASCULAR DISEASE RISK: THE AIM-HIGH TRIAL (ATHEROTHROMBOSIS INTERVENTION IN METABOLIC SYNDROME WITH LOW HDL/HIGH TRIGLYCERIDES: IMPACT ON GLOBAL HEALTH OUTCOMES)](https://www.jacc.org/cms/asset/784e5dcc-b1da-4ada-b176-fbd6eb86de95/s0735-1097(17)35109-4.fp.png)
COMBINED LDL-C AND LIPOPROTEIN (A) LEVELS IN PREDICTION OF RESIDUAL ATHEROSCLEROTIC CARDIOVASCULAR DISEASE RISK: THE AIM-HIGH TRIAL (ATHEROTHROMBOSIS INTERVENTION IN METABOLIC SYNDROME WITH LOW HDL/HIGH TRIGLYCERIDES: IMPACT ON GLOBAL HEALTH OUTCOMES)
![Impulse Dynamics Announces First Patient Enrolled in AIM HIGHer — Implantable Device Trial to Treat Heart Failure in Higher EF Population | DAIC Impulse Dynamics Announces First Patient Enrolled in AIM HIGHer — Implantable Device Trial to Treat Heart Failure in Higher EF Population | DAIC](http://www.dicardiology.com/sites/default/files/Aim%20HIGHer.jpeg)
Impulse Dynamics Announces First Patient Enrolled in AIM HIGHer — Implantable Device Trial to Treat Heart Failure in Higher EF Population | DAIC
![COMBINED LDL-C AND LIPOPROTEIN (A) LEVELS IN PREDICTION OF RESIDUAL ATHEROSCLEROTIC CARDIOVASCULAR DISEASE RISK: THE AIM-HIGH TRIAL (ATHEROTHROMBOSIS INTERVENTION IN METABOLIC SYNDROME WITH LOW HDL/HIGH TRIGLYCERIDES: IMPACT ON GLOBAL HEALTH OUTCOMES) COMBINED LDL-C AND LIPOPROTEIN (A) LEVELS IN PREDICTION OF RESIDUAL ATHEROSCLEROTIC CARDIOVASCULAR DISEASE RISK: THE AIM-HIGH TRIAL (ATHEROTHROMBOSIS INTERVENTION IN METABOLIC SYNDROME WITH LOW HDL/HIGH TRIGLYCERIDES: IMPACT ON GLOBAL HEALTH OUTCOMES)](https://www.jacc.org/cms/asset/7e41b04f-74ea-4060-822c-5015416bd418/fx1.jpg)